Pharmacokinetics of biosynthetic human proinsulin following intravenous and subcutaneous administration in metabolically healthy volunteers. 1988

T R Zilker, and I P Gray, and C N Hales, and K Wahl, and R Ermler, and A Lebender, and G Heinzel, and P Bottermann
II. Medizinische Klinik der Technischen Universität München, Germany.

40 pmol of biosynthetic human proinsulin was administered to 8 healthy volunteers by intravenous and by subcutaneous route. Following proinsulin administration, venous blood was collected in regular intervals within which proinsulin was determined by a specific radioimmunometric assay with monoclonal antibodies. The proinsulin concentration was determined simultaneously with the insulin and C-peptide radioimmunoassay. Through this investigation the following kinetic parameters were found: The kinetics of the biosynthetic human proinsulin can be best described by the 3-compartment model. The dominant biological half-life was 92 minutes. In intravenous proinsulin administration a proinsulin mean transit time of 80 minutes was found, whereas in subcutaneous administration a proinsulin retention time of 225 minutes was measured. The mean resorption velocity of the subcutaneously applied proinsulin amounted to 145 minutes. Two lag times for subcutaneous resorption can be described, a short one with 9.4 minutes and a long one with 65 minutes. The initial distribution volume for proinsulin was 3.8 l, whereas the distribution volume after complete distribution was 9.3 l. The mean total metabolic clearance was determined with 120 ml/min. Since no difference for the proinsulin concentration was found using the 3 different determination methods a peripheral proinsulin conversion to insulin and C-peptide is not likely. The basal endogenous secretion rate for proinsulin is 68.7 pmol per hour.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D011384 Proinsulin A pancreatic polypeptide of about 110 amino acids, depending on the species, that is the precursor of insulin. Proinsulin, produced by the PANCREATIC BETA CELLS, is comprised sequentially of the N-terminal B-chain, the proteolytically removable connecting C-peptide, and the C-terminal A-chain. It also contains three disulfide bonds, two between A-chain and B-chain. After cleavage at two locations, insulin and C-peptide are the secreted products. Intact proinsulin with low bioactivity also is secreted in small amounts.
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

T R Zilker, and I P Gray, and C N Hales, and K Wahl, and R Ermler, and A Lebender, and G Heinzel, and P Bottermann
January 1984, European journal of drug metabolism and pharmacokinetics,
T R Zilker, and I P Gray, and C N Hales, and K Wahl, and R Ermler, and A Lebender, and G Heinzel, and P Bottermann
January 1986, British journal of clinical pharmacology,
T R Zilker, and I P Gray, and C N Hales, and K Wahl, and R Ermler, and A Lebender, and G Heinzel, and P Bottermann
November 1983, International journal of clinical pharmacology, therapy, and toxicology,
T R Zilker, and I P Gray, and C N Hales, and K Wahl, and R Ermler, and A Lebender, and G Heinzel, and P Bottermann
November 1990, Blood,
T R Zilker, and I P Gray, and C N Hales, and K Wahl, and R Ermler, and A Lebender, and G Heinzel, and P Bottermann
January 2018, Lupus science & medicine,
T R Zilker, and I P Gray, and C N Hales, and K Wahl, and R Ermler, and A Lebender, and G Heinzel, and P Bottermann
March 1991, Thrombosis research,
T R Zilker, and I P Gray, and C N Hales, and K Wahl, and R Ermler, and A Lebender, and G Heinzel, and P Bottermann
February 2022, Clinical pharmacology in drug development,
T R Zilker, and I P Gray, and C N Hales, and K Wahl, and R Ermler, and A Lebender, and G Heinzel, and P Bottermann
August 2010, Antimicrobial agents and chemotherapy,
T R Zilker, and I P Gray, and C N Hales, and K Wahl, and R Ermler, and A Lebender, and G Heinzel, and P Bottermann
July 2004, British journal of clinical pharmacology,
T R Zilker, and I P Gray, and C N Hales, and K Wahl, and R Ermler, and A Lebender, and G Heinzel, and P Bottermann
April 1994, Journal of pharmacokinetics and biopharmaceutics,
Copied contents to your clipboard!